Why Emergent BioSolutions Crashed Today
Emergent BioSolutions (NYSE: EBS) was a dog of a stock Thursday, plummeting to close down by over 13%. This followed news that the company apparently erred in the production process of Johnson & Johnson's (NYSE: JNJ) recently authorized coronavirus vaccine.
Johnson & Johnson claimed that one batch of the vaccine manufactured at Emergent's Baltimore facility did not meet its quality standards, and thus could not be used. It did not specify the number of affected doses.
Source Fool.com